Sign up Australia
Proactive Investors - Run By Investors For Investors

Cynata Therapeutics’ market-disruptive regenerative medicines complete world-first trial

Killian Kelly, vice president product development at Cynata Therapeutics Ltd (ASX:CYP), spoke to Proactive Investors at the ASX Small and Mid-Cap Conference in Sydney.

Cynata Therapeutics has met the clinical endpoints of a Phase 1 trial of its Cymerus mesenchymal stem cell (MSC) product candidate in people with steroid-resistant acute graft-versus-host disease (GvHD). The biotech company reported it had achieved a world first with the trial completion.

Meet Great Boulder Resources Ltd, Mainstream Group Holdings Ltd, Blackstone Minerals Ltd, Pacific American Coal Ltd and Reward Minerals Ltd at our event, Sydney , 19 November 2018. Register here »
View full CYP profile View Profile

Cynata Therapeutics Ltd Timeline

© Proactive Investors 2018

Proactive Investors Australia PTY LTD ACN:132787654 ABN:19132787654.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use